

Peter M A Calverley

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9420366/peter-m-a-calverley-publications-by-year.pdf>

Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

148
papers

22,653
citations

53
h-index

150
g-index

167
ext. papers

25,808
ext. citations

11.6
avg, IF

6.43
L-index

#	Paper	IF	Citations
148	A Pooled Analysis of Mortality in Patients with COPD Receiving Dual Bronchodilation with and without Additional Inhaled Corticosteroid.. <i>International Journal of COPD</i> , 2022 , 17, 545-558	3	3
147	Markers of disease activity in COPD: an 8-year mortality study in the ECLIPSE cohort. <i>European Respiratory Journal</i> , 2021 , 57,	13.6	6
146	Treatment Trials in Young Patients with COPD and Pre-COPD Patients: Time to Move Forward. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 ,	10.2	7
145	COPD in the time of COVID-19. <i>EclinicalMedicine</i> , 2021 , 34, 100832	11.3	
144	Challenging the obesity paradox: extreme obesity and COPD mortality in the SUMMIT trial. <i>ERJ Open Research</i> , 2021 , 7,	3.5	2
143	Pharmacotherapy and Lung Function Decline in Patients with Chronic Obstructive Pulmonary Disease. A Systematic Review. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 , 203, 689-698	10.2	10
142	Mortality and Exacerbation Risk by Body Mass Index in Patients with COPD in TIOSPIR and UPLIFT. <i>Annals of the American Thoracic Society</i> , 2021 ,	4.7	1
141	Overnight variation in tidal expiratory flow limitation in COPD patients and its correction: an observational study.. <i>Respiratory Research</i> , 2021 , 22, 319	7.3	1
140	Machine Learning and Prediction of All-Cause Mortality in COPD. <i>Chest</i> , 2020 , 158, 952-964	5.3	15
139	FEV is a stronger mortality predictor than FVC in patients with moderate COPD and with an increased risk for cardiovascular disease. <i>International Journal of COPD</i> , 2020 , 15, 1135-1142	3	11
138	Blood eosinophils as a biomarker of future COPD exacerbation risk: pooled data from 11 clinical trials. <i>Respiratory Research</i> , 2020 , 21, 240	7.3	14
137	Tiotropium/Olodaterol Decreases Exacerbation Rates Compared with Tiotropium in a Range of Patients with COPD: Pooled Analysis of the TONADO/DYNAGITO Trials. <i>Advances in Therapy</i> , 2020 , 37, 4266-4279	4.1	4
136	COPD Maintenance Therapy with Tiotropium/Olodaterol Compared with Tiotropium: An Analysis in the Absence of Additional ICS Therapy. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2020 , 17, 477-484	2	
135	Serum biomarkers and outcomes in patients with moderate COPD: a substudy of the randomised SUMMIT trial. <i>BMJ Open Respiratory Research</i> , 2019 , 6, e000431	5.6	18
134	Impact of pre-enrolment medication use on clinical outcomes in SUMMIT. <i>ERJ Open Research</i> , 2019 , 5,	3.5	3
133	Regional differences in rate of FEV decline in COPD: lessons from SUMMIT. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	1
132	Maintenance rehabilitation for chronic obstructive pulmonary disease. <i>The Cochrane Library</i> , 2019 ,	5.2	78

131	Impact of smoking status and concomitant medications on the effect of high-dose N-acetylcysteine on chronic obstructive pulmonary disease exacerbations: A post-hoc analysis of the PANTHEON study. <i>Respiratory Medicine</i> , 2019 , 147, 37-43	4.6	11
130	Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial. <i>Lancet Respiratory Medicine</i> , 2018 , 6, 337-344	35.1	116
129	Long-Acting βAgonist/Inhaled Corticosteroid in Patients with Chronic Obstructive Pulmonary Disease with Cardiovascular Disease or Risk: A Factorial Analysis of the SUMMIT Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018 , 197, 1641-1644	10.2	3
128	Telemonitoring in Chronic Obstructive Pulmonary Disease (CHROMED). A Randomized Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018 , 198, 620-628	10.2	70
127	The Effect of Defining Chronic Obstructive Pulmonary Disease by the Lower Limit of Normal of FEV ₁ /FVC Ratio in Tiotropium Safety and Performance in RespiMat Participants. <i>Annals of the American Thoracic Society</i> , 2018 , 15, 200-208	4.7	9
126	Cardiac Troponin I and Cardiovascular Risk in Patients With Chronic Obstructive Pulmonary Disease. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 1126-1137	15.1	31
125	Blood pressure, heart rate, and mortality in chronic obstructive pulmonary disease: the SUMMIT trial. <i>European Heart Journal</i> , 2018 , 39, 3128-3134	9.5	17
124	Fluticasone Furoate, Vilanterol, and Lung Function Decline in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018 , 197, 47-55	10.2	34
123	Safety of tiotropium/olodaterol in chronic obstructive pulmonary disease: pooled analysis of three large, 52-week, randomized clinical trials. <i>Respiratory Medicine</i> , 2018 , 143, 67-73	4.6	15
122	Determinants of Response to Roflumilast in Severe Chronic Obstructive Pulmonary Disease. Pooled Analysis of Two Randomized Trials. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018 , 198, 1268-1278	10.2	43
121	A Light in the Darkness? The FLAME Trial, Blood Eosinophils, and Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 195, 1125-1127	10.2	5
120	Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. <i>European Respiratory Journal</i> , 2017 , 49,	13.6	256
119	Eosinophilia, Frequent Exacerbations, and Steroid Response in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 196, 1219-1221	10.2	81
118	Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study. <i>European Respiratory Journal</i> , 2017 , 50,	13.6	48
117	Breathlessness despite optimal pathophysiological treatment: on the relevance of being chronic. <i>European Respiratory Journal</i> , 2017 , 50,	13.6	2
116	A randomised, placebo-controlled trial of anti-interleukin-1 receptor 1 monoclonal antibody MEDI8968 in chronic obstructive pulmonary disease. <i>Respiratory Research</i> , 2017 , 18, 153	7.3	45
115	The effect of COPD severity and study duration on exacerbation outcome in randomized controlled trials. <i>International Journal of COPD</i> , 2017 , 12, 1457-1468	3	5
114	Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. <i>European Respiratory Journal</i> , 2017 , 50,	13.6	89

113	Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: The SUMMIT trial. <i>Respiratory Medicine</i> , 2017 , 131, 27-34	4.6	21
112	Triple Therapy in COPD: What We Know and What We Don't. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2017 , 14, 648-662	2	23
111	Effect of roflumilast in patients with severe COPD and a history of hospitalisation. <i>European Respiratory Journal</i> , 2017 , 50,	13.6	24
110	Effect of Fluticasone Furoate and Vilanterol on Exacerbations of Chronic Obstructive Pulmonary Disease in Patients with Moderate Airflow Obstruction. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 195, 881-888	10.2	38
109	COPD therapy: if two is good, is three better?. <i>Lancet, The</i> , 2016 , 388, 937-8	40	4
108	Effect of tiotropium on night-time awakening and daily rescue medication use in patients with COPD. <i>Respiratory Research</i> , 2016 , 17, 27	7.3	7
107	Blood eosinophils as a marker of response to inhaled corticosteroids in COPD. <i>European Respiratory Journal</i> , 2016 , 47, 1374-82	13.6	159
106	Lung function changes over time following withdrawal of inhaled corticosteroids in patients with severe COPD. <i>European Respiratory Journal</i> , 2016 , 47, 651-4	13.6	16
105	Roflumilast: a review of its use in the treatment of COPD. <i>International Journal of COPD</i> , 2016 , 11, 81-903		89
104	The effects of neoadjuvant chemoradiotherapy and an in-hospital exercise training programme on physical fitness and quality of life in locally advanced rectal cancer patients (The EMPOWER Trial): study protocol for a randomised controlled trial. <i>Trials</i> , 2016 , 17, 24	2.8	15
103	Tiotropium Respimat(®) Versus HandiHaler(®): Comparison of Bronchodilator Efficacy of Various Doses in Clinical Trials. <i>Advances in Therapy</i> , 2016 , 33, 786-93	4.1	2
102	Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. <i>Lancet Respiratory Medicine, the</i> , 2016 , 4, 390-8	35.1	271
101	Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. <i>Lancet, The</i> , 2016 , 387, 1817-26	40	263
100	Sarcopenic Obesity, Functional Outcomes, and Systemic Inflammation in Patients With Chronic Obstructive Pulmonary Disease. <i>Journal of the American Medical Directors Association</i> , 2016 , 17, 712-8	5.9	41
99	Determinants of exercise-induced oxygen desaturation including pulmonary emphysema in COPD: Results from the ECLIPSE study. <i>Respiratory Medicine</i> , 2016 , 119, 87-95	4.6	21
98	A rational approach to single, dual and triple therapy in COPD. <i>Respirology</i> , 2016 , 21, 581-9	3.6	12
97	Identification of five chronic obstructive pulmonary disease subgroups with different prognoses in the ECLIPSE cohort using cluster analysis. <i>Annals of the American Thoracic Society</i> , 2015 , 12, 303-12	4.7	93
96	Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. <i>Annals of the American Thoracic Society</i> , 2015 , 12, 27-34	4.7	98

95	Predicting loss of lung function in healthy people. <i>Lancet Respiratory Medicine</i> , 2015 , 3, 590-1	35.1	
94	Large trials, new knowledge: the changing face of COPD management. <i>European Respiratory Journal</i> , 2015 , 45, 1692-703	13.6	11
93	New Pharmacotherapeutic Approaches for Chronic Obstructive Pulmonary Disease. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2015 , 36, 523-42	3.9	5
92	Effects of different antibiotic classes on airway bacteria in stable COPD using culture and molecular techniques: a randomised controlled trial. <i>Thorax</i> , 2015 , 70, 930-8	7.3	45
91	Mortality and drug therapy in patients with chronic obstructive pulmonary disease: a network meta-analysis. <i>BMC Pulmonary Medicine</i> , 2015 , 15, 145	3.5	9
90	Safety and efficacy of tiotropium Respimat versus HandiHaler in patients naive to treatment with inhaled anticholinergics: a post hoc analysis of the TIOSPIR trial. <i>Npj Primary Care Respiratory Medicine</i> , 2015 , 25, 15067	3.2	10
89	The Tiotropium Safety and Performance in Respimat [®] (TIOSPIR [®]) Trial: Spirometry Outcomes. <i>Respiratory Research</i> , 2015 , 16, 107	7.3	16
88	A score to predict short-term risk of COPD exacerbations (SCOPEX). <i>International Journal of COPD</i> , 2015 , 10, 201-9	3	38
87	The Association Between Heroin Inhalation and Early Onset Emphysema. <i>Chest</i> , 2015 , 148, 1156-1163	5.3	18
86	Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. <i>Lancet, The</i> , 2015 , 385, 857-66	4.0	248
85	Withdrawal of inhaled glucocorticoids and exacerbations of COPD. <i>New England Journal of Medicine</i> , 2014 , 371, 1285-94	59.2	407
84	Pooled subpopulation analyses of the effects of roflumilast on exacerbations and lung function in COPD. <i>Respiratory Medicine</i> , 2014 , 108, 366-75	4.6	21
83	Lessons from ECLIPSE: a review of COPD biomarkers. <i>Thorax</i> , 2014 , 69, 666-72	7.3	102
82	Should we view chronic obstructive pulmonary disease differently after ECLIPSE? A clinical perspective from the study team. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014 , 189, 1022-30	10.2	117
81	Response. <i>Chest</i> , 2014 , 145, 428	5.3	1
80	Prevention of Exacerbations in Chronic Obstructive Pulmonary Disease: Knowns and Unknowns. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2014 , 1, 166-184	2.7	19
79	Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis. <i>European Respiratory Journal</i> , 2014 , 44, 789-91	13.6	115
78	Non-emphysematous chronic obstructive pulmonary disease is associated with diabetes mellitus. <i>BMC Pulmonary Medicine</i> , 2014 , 14, 164	3.5	39

77	Use of inhaled corticosteroids in patients with COPD and the risk of TB and influenza: A systematic review and meta-analysis of randomized controlled trials. a systematic review and meta-analysis of randomized controlled trials. <i>Chest</i> , 2014 , 145, 1286-1297	5.3	61
76	Roflumilast and dyspnea in patients with moderate to very severe chronic obstructive pulmonary disease: a pooled analysis of four clinical trials. <i>International Journal of COPD</i> , 2014 , 9, 657-73	3	10
75	Current drug treatment, chronic and acute. <i>Clinics in Chest Medicine</i> , 2014 , 35, 177-89	5.3	7
74	Stepwise withdrawal of inhaled corticosteroids in COPD patients receiving dual bronchodilation: WISDOM study design and rationale. <i>Respiratory Medicine</i> , 2014 , 108, 593-9	4.6	36
73	New treatments for COPD: many miles still to go. <i>Lancet Respiratory Medicine</i> , 2014 , 2, 6-7	35.1	6
72	The Association Between Dietary Intake and Phenotypical Characteristics of COPD in the ECLIPSE Cohort. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2014 , 1, 115-124	2.7	6
71	Pharmacological Treatment: an Update 2014 , 311-321		
70	The Tiotropium Safety and Performance in Respimat Trial (TIOSPIR), a large scale, randomized, controlled, parallel-group trial-design and rationale. <i>Respiratory Research</i> , 2013 , 14, 40	7.3	44
69	Bronchodilator reversibility in chronic obstructive pulmonary disease: use and limitations. <i>Lancet Respiratory Medicine</i> , 2013 , 1, 564-73	35.1	50
68	Tiotropium Respimat inhaler and the risk of death in COPD. <i>New England Journal of Medicine</i> , 2013 , 369, 1491-501	59.2	270
67	The Study to Understand Mortality and Morbidity in COPD (SUMMIT) study protocol. <i>European Respiratory Journal</i> , 2013 , 41, 1017-22	13.6	65
66	Fluticasone furoate/vilanterol (100/25; 200/25 μ) improves lung function in COPD: a randomised trial. <i>Respiratory Medicine</i> , 2013 , 107, 550-9	4.6	92
65	Fluticasone furoate and vilanterol for COPD - authorsTreply. <i>Lancet Respiratory Medicine</i> , 2013 , 1, e21-2	35.1	1
64	Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. <i>Lancet Respiratory Medicine</i> , 2013 , 1, 210-23	35.1	249
63	Six-minute-walk test in chronic obstructive pulmonary disease: minimal clinically important difference for death or hospitalization. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013 , 187, 382-6	10.2	206
62	Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. <i>European Respiratory Journal</i> , 2013 , 42, 636-46	13.6	139
61	Efficacy of roflumilast in the COPD frequent exacerbator phenotype. <i>Chest</i> , 2013 , 143, 1302-1311	5.3	84
60	Cardiovascular safety in patients receiving roflumilast for the treatment of COPD. <i>Chest</i> , 2013 , 144, 758-765	5.3	72

59	The Tiotropium Safety and Performance in RespiMat (TIOspir) trial: Bronchodilator efficacy in a spirometry substudy. <i>Chest</i> , 2013 , 144, 1027A	5.3	2
58	How to write research papers and grants: 2011 Asian Pacific Society for Respiratory Annual Scientific Meeting Postgraduate Session. <i>Respirology</i> , 2012 , 17, 792-801	3.6	3
57	Side-effects of roflumilast. AuthorsTrepley. <i>Lancet, The</i> , 2012 , 379, 711-712	4.0	3
56	Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease. <i>Thorax</i> , 2012 , 67, 701-8	7.3	122
55	Predicting outcomes from 6-minute walk distance in chronic obstructive pulmonary disease. <i>Journal of the American Medical Directors Association</i> , 2012 , 13, 291-7	5.9	167
54	Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012 , 185, 1065-72	10.2	288
53	Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocol. <i>International Journal of COPD</i> , 2012 , 7, 375-82	3	23
52	Risk of misdiagnosis, health-related quality of life, and BMI in patients who are overweight with doctor-diagnosed asthma. <i>Chest</i> , 2012 , 141, 616-624	5.3	38
51	Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. <i>PLoS ONE</i> , 2012 , 7, e37483	3.7	521
50	Respiratory system impedance with impulse oscillometry in healthy and COPD subjects: ECLIPSE baseline results. <i>Respiratory Medicine</i> , 2011 , 105, 1069-78	4.6	95
49	Reported pneumonia in patients with COPD: findings from the INSPIRE study. <i>Chest</i> , 2011 , 139, 505-512	5.3	130
48	A new perspective on optimal care for patients with COPD. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2011 , 20, 205-9		26
47	Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD. <i>Respiratory Research</i> , 2011 , 12, 18	7.3	194
46	Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease. The TORCH experience. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011 , 183, 317-22	10.2	122
45	Changes in forced expiratory volume in 1 second over time in COPD. <i>New England Journal of Medicine</i> , 2011 , 365, 1184-92	59.2	654
44	Pharmacological Therapy: Inhaled Corticosteroids 2011 , 115-127		
43	Better lungs for better legs: novel bronchodilator effects in COPD. <i>Thorax</i> , 2010 , 65, 573-5	7.3	
42	Susceptibility to exacerbation in chronic obstructive pulmonary disease. <i>New England Journal of Medicine</i> , 2010 , 363, 1128-38	59.2	1840

41	Determinants of poor 6-min walking distance in patients with COPD: the ECLIPSE cohort. <i>Respiratory Medicine</i> , 2010 , 104, 849-57	4.6	148
40	Cardiovascular events in patients with COPD: TORCH study results. <i>Thorax</i> , 2010 , 65, 719-25	7.3	142
39	Maintenance rehabilitation for chronic obstructive pulmonary disease. <i>The Cochrane Library</i> , 2010 ,	5.2	2
38	Treatment options in chronic obstructive pulmonary disease. <i>The Prescriber</i> , 2010 , 21, 14-24	0.4	
37	Characterisation of COPD heterogeneity in the ECLIPSE cohort. <i>Respiratory Research</i> , 2010 , 11, 122	7.3	752
36	Prevalence and progression of osteoporosis in patients with COPD: results from the Towards a Revolution in COPD Health study. <i>Chest</i> , 2009 , 136, 1456-1465	5.3	202
35	Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. <i>Respiratory Research</i> , 2009 , 10, 59	7.3	234
34	Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. <i>Lancet, The</i> , 2009 , 374, 712-9	4.0	155
33	Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. <i>Lancet, The</i> , 2009 , 374, 695-703	4.0	469
32	Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. <i>Lancet, The</i> , 2009 , 374, 685-94	4.0	591
31	UPLIFTing care for chronic obstructive pulmonary disease. <i>Lancet, The</i> , 2009 , 374, 1129-30	4.0	2
30	Budesonide and risk of pneumonia [AuthorsReply]. <i>Lancet, The</i> , 2009 , 374, 2051-2052	4.0	2
29	One-year treatment with mometasone furoate in chronic obstructive pulmonary disease. <i>Respiratory Research</i> , 2008 , 9, 73	7.3	36
28	Identifying COPD patients at increased risk of mortality: predictive value of clinical study baseline data. <i>Respiratory Medicine</i> , 2008 , 102, 1615-24	4.6	24
27	A PEACE-ful solution to COPD exacerbations?. <i>Lancet, The</i> , 2008 , 371, 1975-6	4.0	8
26	The volumetric response to bronchodilators in stable chronic obstructive pulmonary disease. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2008 , 5, 147-52	2	27
25	The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008 , 177, 19-26	10.2	636
24	Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008 , 178, 332-8	10.2	566

23	Management of Patients with COPD: A Comparison of the INSPIRE and TORCH Studies. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008 , 178, 106-107	10.2	
22	Pathological networking: a new approach to understanding COPD. <i>Postgraduate Medical Journal</i> , 2007 , 62, 733-8	2	14
21	Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007 , 176, 154-61	10.2	256
20	Today's management of chronic obstructive pulmonary disease. <i>The Prescriber</i> , 2007 , 18, 50-63	0.4	2
19	Investigating new standards for prophylaxis in reduction of exacerbations--the INSPIRE study methodology. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2007 , 4, 177-83	2	22
18	The effect of bronchodilators and oxygen alone and in combination on self-paced exercise performance in stable COPD. <i>Respiratory Medicine</i> , 2007 , 101, 746-53	4.6	20
17	What have we learned from large drug treatment trials in COPD?. <i>Lancet, The</i> , 2007 , 370, 774-85	40	47
16	Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. <i>New England Journal of Medicine</i> , 2007 , 356, 775-89	59.2	2457
15	Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007 , 176, 532-55	10.2	5242
14	Is airway inflammation in chronic obstructive pulmonary disease (COPD) a risk factor for cardiovascular events?. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2006 , 3, 233-42	2	33
13	The severity of airways obstruction as a determinant of treatment response in COPD. <i>International Journal of COPD</i> , 2006 , 1, 209-18	3	12
12	Treatments for COPD. <i>Respiratory Medicine</i> , 2005 , 99 Suppl B, S28-40	4.6	21
11	Minimal clinically important difference--exacerbations of COPD. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2005 , 2, 143-8	2	33
10	Lung mechanics and dyspnea during exacerbations of chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2005 , 172, 1510-6	10.2	129
9	The role of corticosteroids in chronic obstructive pulmonary disease. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2005 , 26, 235-45	3.9	18
8	Development of a population-based screening questionnaire for COPD. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2005 , 2, 225-32	2	26
7	Effect of corticosteroids on exacerbations of asthma and chronic obstructive pulmonary disease. <i>Proceedings of the American Thoracic Society</i> , 2004 , 1, 161-6		11
6	Are inhaled corticosteroids systemic therapy for chronic obstructive pulmonary disease?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004 , 170, 721-2	10.2	13

5	Reducing the frequency and severity of exacerbations of chronic obstructive pulmonary disease. <i>Proceedings of the American Thoracic Society</i> , 2004 , 1, 121-4		22
4	Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. <i>Respiratory Medicine</i> , 2004 , 98, 1045-50	4.6	67
3	Withdrawal from treatment as an outcome in the ISOLDE study of COPD. <i>Chest</i> , 2003 , 124, 1350-6	5.3	86
2	Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. <i>Lancet, The</i> , 2003 , 361, 449-56	4.0	961
1	Cough in Chronic Obstructive Pulmonary Disease125-135		